http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Juraj Majtan,Jana Bohova,Emanuel Prochazka,Jaroslav Klaudiny 한국식품영양과학회 2014 Journal of medicinal food Vol.17 No.2
Although hydrogen peroxide (H2O2) is one of the major antibacterial factors in most honeys, it does not accumulate in medical-grade manuka honey. The goal of this study was to investigate the effect of artificially added methylglyoxal (MGO) on H2O2 accumulation in natural non-manuka honeys. H2O2 concentrations in the honey solutions were determined using a fluorimetric assay. Two, the most potent H2O2 producers honeydew honeys were mixed with MGO at final concentrations of 250, 500, and 1000 mg/kg, and incubated for 4 days at 37 C. Subsequently, H2O2 concentrations were determined in 50% (wt/vol) MGO supplemented honey solutions. In vitro crosslinking of the enzyme glucose oxidase (GOX) after incubation with MGO was determined by sodium dodecyl sulfate–polyacrylamide gel electrophoresis. Tested honeys at a concentration of 50% (wt/vol) accumulated up to 495.8 – 9.1 lM H2O2 in 24 h. The most potent producers were the two honeydew honeys, whose 50% solutions accumulated 306.9 – 6.8 and 495.8 – 9.1 lM H2O2, respectively. Levels of H2O2 increased significantly over time in both honey solutions. Contrary to this, the MGOtreated honeys generated significantly lower amounts of H2O2 (P < .001), and this reduction was dose dependent. In addition, MGO-treated GOX formed high molecular weight adducts with increasing time of incubation accompanied by loss of its enzymatic activity. High levels of MGO in manuka honey, by modifying the enzyme GOX, might be responsible for suppressing H2O2 generation. These data highlight the detrimental effect of MGO on significant proteinaceous components of manuka honey.
( Ondrej Krystynik ),( Rudolf Chlup ),( Katerina Loykova ),( Vera Loykova ),( Jaromira Gajdova ),( Vlastimil Prochazka ),( Josef Zadrazil ) 대한내과학회 2014 대한내과학회 추계학술대회 Vol.2014 No.1
Background: Since the year 1978 continuous subcutaneous insulin infusion (CSII) became the best near-physiological way of insulin substitution. The purpose of this study was to answer these questions: 1) how many persons have been put on an insulin pump since 1995 2) how many of them rejected the insulin pump 3) how many of them were switched to another kind of treatment 4) how many of CSII-treated patients died Methods: The study was carried out in a diabetes center in the course of 18 years (1995-2012). Various types of insulin pumps were applied and upgraded shortly beyond the date of their 48-month expiration period. The indications for CSII were insuffi cient diabetes control, progression of complications, pregnancy and patient´s motivation. Results: A total of 580 patients (aged 11-78 years, 481 treated for T1DM and 99 persons for T2DM) were put on insulin pump in our center (n = 532) or referred with a pump to our center from a children`s department (n = 48) at their age of 18 years. A duration of diabetes varied from 0 to 56 years. Six patients (1%) rejected the pump within 6 years after insertion due to stress related to new technologies. Seven patients (1,2%) were switched to other treatment, three patients had to be switched to other treatment due to their low compliance. Twenty-six pump-treated patients (4,5%) died due to late renal failure (n = 5), myocardial infarction (n = 2), heart failure (n = 12), stroke (n = 2), pneumonia (n = 2), M.Alzheimer (n = 2) or unknown cause (n = 1). Conclusions: Growing numbers of persons with diabetes type 1 and type 2 put on insulin pumps demonstrate increasing motivation of patients in recent technology for diabetes treatment.
( Jan Gregar ),( Pavla Luzna ),( Jiri Ehrmann Jr ),( Vlastimil Prochazka ),( Premek Falt ),( Stepan Suchanek ),( Josef Srovnal ) 대한내과학회 2014 대한내과학회 추계학술대회 Vol.2014 No.1
Background: Barrett`s esophagus (BE) is premalignant condition. Sequence of histological changes from intestinal metaplasia (IM) through low-grade dysplasia (LG) up to high-grade dysplasia and adenocarcinoma. Endoscopy and histopathology assessment is "gold standard" for diagnosis. But immunohistochemistry can be helpful for stratify-cation and assessment of risk of dysplasia/malignancy. Methods: The aim of the study was to investigate the role and the diagnostic potential of the immunohistochemistry in the disease progression. BE was inspected by endoscopy (narrow band imaging and zoom) and biopsies from all suspicious lesions were obtained for histopathological assessment (50 patients, diagnosed in the last 3 years). 25 patients with non-dysplastic BE (IM) and 25 patients with low-grade dysplasia BE (LG). Bioptic samples (50 patients) were used for indirect immunohistochemical labelling and analysis of expression of proteins playing an important role during BE progression (CDX2, MUC2, H2AX and p53). Expression of selected proteins was assessed semiquantitatively by “histoscore“(H score), which is the result of intensity of staining (0 = negative, 1 = weakly visible intensity, 2 = ligh brown intensity, 3 = dark brown intensity of staining) multiplied by percentage of positive cells. Results: Immunohistochemical detection of expression of selected proteins showed the rising histoscore of all selected proteins in BE with LG dysplasia against non-dysplastic IM BE: CDX (16.7% vs. 33.3%), MUC2 (6.3% vs. 36.4%), H2AX (25.9% vs. 44.4%) and p53 (75.0% vs. 89.6%). Statistical significance was found in CDX, MUC2 and H2AX proteins. Conclusions: Immunohistochemistry of selected proteins could be helpful method how to estimate progression of BE, and how to select patients with risk of dysplastic changes in BE.